Stockpolly
Search
Delisting risk
TPST · NASDAQ · Biotechnology

Tempest Therapeutics (TPST)

Develops in vivo CAR-T candidates for autoimmune disease and cancer.

$1.09
Pre-market−0.01 (−0.80%)
At close$1.10(+4.76%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue0000000000220
Gross profit0000000000−220
7881011141184465
Research & development4446811841102
234433343453
General & administrative234433343453
Other expenses000000000000
Operating income−7−8−8−10−11−14−11−8−4−4−28−5
000000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−7−7−8−10−11−14−11−8−4−4−28−5
Net income from continuing operations−7−7−8−10−11−14−11−8−4−4−28−5
Net income−7−7−8−10−11−14−11−8−4−4−28−5
EPS, basic−$0.48−$0.35−$0.36−$0.42−$0.41−$0.50−$3.16−$2.07−$0.79−$0.82−$2.53−$0.34
EPS, diluted−$0.48−$0.35−$0.36−$0.42−$0.41−$0.50−$3.16−$2.07−$0.79−$0.82−$2.53−$0.34
Weighted average shares, basic14222223262834441115
Weighted average shares, diluted14222223262834441115
EBITDA−6−7−7−9−10−14−11−8−3−4−28−5
Depreciation & amortization000000000000
EBIT−6−7−8−9−10−14−11−8−4−4−28−5